RPG Life Sciences (RPGLIFE) | Financial Analysis & Statements
RPG Life Sciences Ltd. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.7B
Gross Profit
1.1B
64.47%
Operating Income
303.3M
17.96%
Net Income
262.9M
15.56%
EPS (Diluted)
₹15.90
Balance Sheet Metrics
Total Assets
6.6B
Total Liabilities
1.3B
Shareholders Equity
5.3B
Debt to Equity
0.24
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
RPG Life Sciences Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 6.5B | 5.8B | 5.1B | 4.4B | 3.8B |
| Cost of Goods Sold | 2.2B | 1.9B | 1.8B | 1.5B | 1.4B |
| Gross Profit | 4.2B | 3.8B | 3.3B | 2.9B | 2.5B |
| Gross Margin % | 65.4% | 66.4% | 65.0% | 65.6% | 64.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 729.3M | 609.0M | 558.8M | 535.6M | 421.5M |
| Other Operating Expenses | 652.1M | 637.2M | 552.1M | 474.2M | 417.2M |
| Total Operating Expenses | 1.4B | 1.2B | 1.1B | 1.0B | 838.7M |
| Operating Income | 1.4B | 1.1B | 888.8M | 717.2M | 547.2M |
| Operating Margin % | 21.7% | 19.4% | 17.5% | 16.4% | 14.3% |
| Non-Operating Items | |||||
| Interest Income | 32.1M | 14.2M | 27.3M | 13.3M | 3.2M |
| Interest Expense | 6.2M | 4.5M | 3.1M | 5.2M | 7.9M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 2.3B | 1.2B | 916.8M | 731.7M | 535.8M |
| Income Tax | 496.4M | 301.8M | 240.4M | 216.9M | 135.8M |
| Effective Tax Rate % | 21.3% | 25.6% | 26.2% | 29.6% | 25.3% |
| Net Income | 1.8B | 876.6M | 676.4M | 514.8M | 400.0M |
| Net Margin % | 28.3% | 15.2% | 13.3% | 11.8% | 10.4% |
| Key Metrics | |||||
| EBITDA | 1.6B | 1.3B | 1.1B | 885.5M | 710.1M |
| EPS (Basic) | ₹110.80 | ₹53.01 | ₹40.90 | ₹31.13 | ₹24.19 |
| EPS (Diluted) | ₹110.80 | ₹53.01 | ₹40.90 | ₹31.13 | ₹24.19 |
| Basic Shares Outstanding | 16539015 | 16539015 | 16539015 | 16539015 | 16539015 |
| Diluted Shares Outstanding | 16539015 | 16539015 | 16539015 | 16539015 | 16539015 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
RPG Life Sciences Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 287.0M | 197.2M | 248.2M | 569.4M | 403.6M |
| Short-term Investments | 2.4B | 1.1B | 899.8M | 128.6M | 15.3M |
| Accounts Receivable | 867.6M | 491.3M | 374.3M | 329.9M | 574.2M |
| Inventory | 929.8M | 1.0B | 950.5M | 829.9M | 583.3M |
| Other Current Assets | 142.1M | 203.1M | 147.3M | 191.6M | 182.1M |
| Total Current Assets | 4.7B | 3.0B | 2.6B | 2.1B | 1.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.6B | 970.3M | 1.0B | 746.4M | 785.0M |
| Goodwill | 227.6M | 280.3M | 334.0M | 346.8M | 371.3M |
| Intangible Assets | 227.6M | 280.3M | 334.0M | 346.8M | 371.3M |
| Long-term Investments | - | 0 | 0 | 0 | - |
| Other Non-Current Assets | 5.0M | 15.1M | 32.5M | 11.8M | 7.2M |
| Total Non-Current Assets | 1.9B | 2.1B | 1.6B | 1.4B | 1.3B |
| Total Assets | 6.6B | 5.1B | 4.2B | 3.4B | 3.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 793.9M | 710.2M | 646.9M | 455.0M | 474.4M |
| Short-term Debt | - | 0 | 100.0K | 6.4M | 12.8M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 67.0M | 52.3M | 62.0M | 55.6M | 64.4M |
| Total Current Liabilities | 1.2B | 1.3B | 1.0B | 801.1M | 796.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | - | - | 0 | 3.0M | 7.4M |
| Deferred Tax Liabilities | - | 0 | 19.7M | 22.6M | 0 |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 74.5M | 70.6M | 89.7M | 87.3M | 72.5M |
| Total Liabilities | 1.3B | 1.4B | 1.1B | 888.4M | 869.4M |
| Equity | |||||
| Common Stock | 132.3M | 132.3M | 132.3M | 132.3M | 132.3M |
| Retained Earnings | 4.7B | 3.2B | 2.5B | 2.0B | 1.6B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 5.3B | 3.7B | 3.1B | 2.6B | 2.2B |
| Key Metrics | |||||
| Total Debt | 0 | 0 | 100.0K | 9.4M | 20.2M |
| Working Capital | 3.5B | 1.7B | 1.6B | 1.3B | 961.6M |
Balance Sheet Composition
RPG Life Sciences Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 2.3B | 1.2B | 916.8M | 731.7M | 535.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | - | - | - | - | - |
| Working Capital Changes | -385.8M | -130.3M | -69.5M | -12.9M | -77.5M |
| Operating Cash Flow | 1.1B | 1.0B | 823.1M | 710.7M | 463.0M |
| Investing Activities | |||||
| Capital Expenditures | 734.4M | -690.8M | -326.5M | -239.5M | -84.6M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | -1.7B | -445.1M | -758.9M | -128.6M | 0 |
| Investment Sales | 477.1M | 330.2M | 0 | 8.9M | 0 |
| Investing Cash Flow | -450.1M | -651.0M | -1.3B | -359.9M | -82.8M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | -264.6M | -198.5M | -158.8M | -119.1M | - |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | 0 | - | -2.7M | -4.2M | -90.7M |
| Financing Cash Flow | -264.6M | -198.5M | -164.3M | -126.4M | -136.7M |
| Free Cash Flow | 418.3M | 251.3M | 580.9M | 408.0M | 497.6M |
| Net Change in Cash | 363.9M | 188.9M | -615.6M | 224.4M | 243.5M |
Cash Flow Trend
RPG Life Sciences Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.43
Forward P/E
70.38
Price to Book
6.01
Price to Sales
4.94
PEG Ratio
0.04
Profitability Ratios
Profit Margin
30.08%
Operating Margin
19.10%
Return on Equity
34.54%
Return on Assets
27.86%
Financial Health
Current Ratio
3.88
Debt to Equity
0.00
Beta
-0.39
Per Share Data
EPS (TTM)
₹122.43
Book Value per Share
₹334.93
Revenue per Share
₹407.36
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RPGLIFE | 33.6B | 16.43 | 6.01 | 34.54% | 30.08% | 0.00 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Gujarat Themis | 35.4B | 73.73 | 13.36 | 19.64% | 29.99% | 27.04 |
Financial data is updated regularly. All figures are in the company's reporting currency.





